Bacteriophage Therapy Market to Surpass US$ 1,652.3 Million by 2030 - Coherent Market Insights

Global Bacteriophage Therapy Market, By Targeted Bacteria (Escherichia coli, Staphylococcus aureus, Streptococcus, Pseudomonas aeruginosa, Salmonella, and Others), By Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis, and Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)), By Route of Administration (Oral, Topical, and Parenteral) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,148.6 million in 2020 and is expected to exhibit a CAGR of 3.7% over the forecast period (2020-2030), as highlighted in a new report published by Coherent Market Insights.

Increasing research and development activities by key players operating in the global bacteriophage therapy market, for the development of novel products, is anticipated to drive the market growth over the forecast period. For instance, in January 2021, Eligo Bioscience announced that it received the award of US$ 1.82 Mn from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) company. CARB-X is led by Boston University while the funding is provided by the Biomedical Advanced Research and Development Authority (BARDA). The award was received by the Eligo Bioscience for promoting research and development of Eligo’s bacteriophage for the treatment against E. coli and K. Pneumonia infections.

Furthermore, increasing product approvals is expected to drive the segment growth over the forecast period. For instance, in November 2020, Adaptive Phage Therapeutics received the U.S. Food Drug Administration (FDA) approval for their PhageBank treatment therapy against infections such as pneumonia and bacteremia/septicemia caused due to Acinetobacter baumannii, Pseudomonas aeruginosa or Staphylococcus aureus in COVID-19 patients.

Global Bacteriophage Therapy Market – Impact of Coronavirus (COVID-19) Pandemic

Key players in the market are focusing on the research and development in bacteriophage therapy for the treatment of novel coronavirus (COVID-19). For instance, in November 2020, Adaptive Phage Therapeutics, Inc. announced that it had initiated an investigational clinical trial study to study the safety and evaluation of phage therapy on the COVID-19 patients with bacterial co-infections. Moreover, in November 2020, Adaptive Phage Therapeutics, Inc. stated that it is focusing on raising funds from the U.S. government agencies and non-governmental bodies in the U.S. for boosting the research and development of PhageBank therapy for the treatment of COVID-19 disease.

Furthermore, various companies are using the phage-based technologies to analyze the antibodies obtained from the blood plasma from the COVID-19 recovered patients, so as to analyze the COVID-19 virus activity. For instance, in April 2020, ProteoGenix, an antibody production company, launched an accelerated therapeutic antibody, which analyzes an immune human antibody obtained from the plasma of a COVID-19 infection survivor, by using the phage display technique, which analyzes the COVID-19 antibodies.

Browse 35 Market Data Tables and 40 Figures spread through 246 Pages and in-depth TOC on “Bacteriophage Therapy Market”- Global Forecast to 2030, By Targeted Bacteria (Escherichia coli, Staphylococcus aureus, Streptococcus, Pseudomonas aeruginosa, Salmonella, and Others), By Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis, and Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)), By Route of Administration (Oral, Topical, and Parenteral) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),

To know the latest trends and insights prevalent in the global bacteriophage therapy market, click the link below:

https://www.coherentmarketinsights.com/market-insight/bacteriophages-therapy-market-2752

North America bacteriophage therapy market is expected to provide significant opportunity to the market players in the near future, owing to increasing regulatory approvals for phage therapies in this region. For instance, in February 2019, University of California San Diego (UCSD) School of Medicine received the U.S. FDA approval to conduct the first U.S. clinical trial of intravenously administered bacteriophage therapy. The proposed trial will be conducted in collaboration with AmpliPhi Biosciences Corporation.

Key Takeaways of the Global Bacteriophage Therapy Market:

• The global bacteriophage therapy market is expected to exhibit a CAGR of 3.7% over the forecast period, owing to increasing antimicrobial resistance rate. According to the Network for the Research and Surveillance of Drug Resistance, in Mexico, from January 2018 to June 2018, a total of 22,943 multidrug resistant strain of bacteria were recorded in Mexico.
• Among targeted bacteria, Streptococcus segment is accounted for largest market share in 2020, owing to pharmaceutical companies focusing on research and development on phage-based therapy for the treatment of pneumonia caused in patients due to streptococcus gram positive bacteria. For instance, in November 2020, Locus Biosciences, Inc. announced that they are developing LBP-KP01, a CRISPR-Cas3-enhanced bacteriophage product targeting Klebsiella pneumonia. LBP-KP01 is a bacteriophage cocktail that is engineered with a DNA genome known as clustered regularly interspaced short palindromic repeats (CRISPR-Cas3), which targets the pneumoniae genome.
• Key players operating in the global bacteriophage therapy market include Armata Pharmaceuticals, Inc., Eliava Biopreparations Ltd., Pherecydes Pharma, Intralytix, Inc., Phagelux, Inc., Nextbiotics, InnoPhage, Ltd, Locus Biosciences, Inc., TechnoPhage, Eligo Bioscience SA, Phagomed Biopharma GmbH., PhagePro, Inc., Adaptive Phage Therapeutics, Enbiotix, Inc., Intodeworld, Inc., BiomX Ltd., Phi Therapeutics, Fixed-phage Ltd., Micreos BV, ContraFect Corporation, and OPTIPHARM Co., Ltd.